There are now three competing approaches to regenerative medicine: embryonic stem cells, induced pluripotent cells, and transdifferentiated cells. In my latest feature article, out in last week's issue of Current Biology, I explored these three options and discussed the implications for medicine and society.
Since writing this piece, one notable side effect occurred to me that I hadn't thought of: the approach of "therapeutic cloning," much debated in around 2004-05, has completely disappeared from the agenda, now that there are options that are both easier and less problematic at the bioethics front.
Regenerative medicine spoilt for choice
Current Biology, Volume 21, Issue 7, R235-R237, 12 April 2011
doi:10.1016/j.cub.2011.03.062
Summary and FREE access to pdf file
Monday, April 18, 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment